BRIEF published on 04/17/2026 at 21:05, 23 days 19 hours ago Innate Pharma Reveals Promising Interim Results in MATISSE Phase 2 Study Clinical Trials Lung Cancer Innate Pharma MATISSE Phase 2 IPH5201
BRIEF published on 04/17/2026 at 21:05, 23 days 19 hours ago Innate Pharma presents interim results from the MATISSE trial at the AACR congress Lung Cancer Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
BRIEF published on 04/17/2026 at 21:05, 23 days 19 hours ago Innate Pharma présente des résultats intermédiaires de l'essai MATISSE au congrès AACR Cancer Du Poumon Innate Pharma AACR 2026 IPH5201 Phase 2 MATISSE
BRIEF published on 04/17/2026 at 21:05, 23 days 19 hours ago Innate Pharma dévoile des résultats intermédiaires prometteurs dans l'étude de phase 2 MATISSE Essais Cliniques Cancer Du Poumon Innate Pharma MATISSE Phase 2 IPH5201
PRESS RELEASE published on 04/17/2026 at 21:00, 23 days 19 hours ago Informations privilégiées / Autres communiqués Innate Pharma présentera des résultats intermédiaires de l'essai de Phase 2 MATISSE évaluant IPH5201 lors d'une session plénière dédiée aux essais cliniques au congrès de l'AACR 2026 Essai Clinique Cancer Du Poumon Innate Pharma AACR 2026 IPH5201
PRESS RELEASE published on 04/17/2026 at 21:00, 23 days 19 hours ago Inside Information / Other news releases Innate Pharma to present interim results of IPH5201 in MATISSE Phase 2 study at AACR 2026. Study aims to enhance NSCLC treatment with anti-CD39 monoclonal antibody NSCLC Innate Pharma AACR 2026 MATISSE Phase 2 IPH5201
BRIEF published on 04/13/2026 at 07:05, 28 days 9 hours ago Innate Pharma Updates Share and Voting Rights as of April 2026 Biotechnology Shares And Voting Rights Innate Pharma April 2026 Euronext Nasdaq
BRIEF published on 04/13/2026 at 07:05, 28 days 9 hours ago Innate Pharma: Capital and Voting Rights Update Voting Rights Biotechnology Actions Immunotherapy Innate Pharma
BRIEF published on 04/13/2026 at 07:05, 28 days 9 hours ago Innate Pharma met à jour ses actions et ses droits de vote à compter d'avril 2026 Biotechnologie Innate Pharma Actions Et Droits De Vote Avril 2026 Euronext Nasdaq
BRIEF published on 04/13/2026 at 07:05, 28 days 9 hours ago Innate Pharma : Mise à Jour du Capital et des Droits de Vote Droits De Vote Biotechnologie Actions Immunothérapie Innate Pharma
Published on 05/11/2026 at 14:30, 1 hour 39 minutes ago Recent Hantavirus On A Cruise Ship Highlights the Need for Broad-Spectrum Antiviral Drugs Such as NV-387, Says NanoViricides
Published on 05/11/2026 at 14:00, 2 hours 9 minutes ago Unusual Machines Accelerates Domestic Battery Manufacturing by Signing a Merger Agreement to Acquire Upgrade Energy
Published on 05/11/2026 at 14:00, 2 hours 9 minutes ago New Horizon Aircraft Ltd. Announces Closing of $20 Million Offering of Common Shares
Published on 05/11/2026 at 14:00, 2 hours 9 minutes ago Colosseum Bankable Feasibility Study Confirms High Margin Gold Project
Published on 05/11/2026 at 14:00, 2 hours 9 minutes ago Ur-Energy Reminds Shareholders and Interested Parties of First Quarter Conference Call and Webcast
Published on 05/11/2026 at 15:55, 14 minutes ago EQS-Adhoc: Accentro Real Estate AG announces deviation from the IDW S6 report and intended increase in the 2025/2027 bond
Published on 05/11/2026 at 15:46, 22 minutes ago Form 8.3 - The Vanguard Group, Inc.: Picton Property Income Limited
Published on 05/11/2026 at 15:44, 24 minutes ago Form 8.3 - The Vanguard Group, Inc.: Intertek Group plc
Published on 05/11/2026 at 10:48, 5 hours 20 minutes ago GUILLEMOT CORPORATION | Weekly report share buyback from May 4 to May 8 2026
Published on 05/11/2026 at 10:48, 5 hours 20 minutes ago GUILLEMOT CORPORATION | Déclaration hebdomadaire des transactions sur actions propres du 4 au 8 mai 2026
Published on 05/11/2026 at 09:16, 6 hours 52 minutes ago ENGIE - Déclaration du nombre total d'actions et de droits de vote au 28 avril 2026
